Skip to main content

Table 2 Plasma levels of MMP-7, TIMP-1, HE4 and CA 125 in tested groups (statistically significant when p < 0.05)

From: Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers

Groups MMP-7
(ng/ml)
TIMP-1
(ng/ml)
HE4
(pmol/L)
CA125
(U/ml)
Ovarian cancer Median Range Stage I a, b4.76
1.98–17.86
a108.35
4.60–328.90
a, b118.70
34.50–1093.80
a66.73
10.60–557.20
Stage II a, b4.73
2.24–18.00
151.70
15.20–839.00
a, b120.90
38.30–1205.70
a, b61.45
9.80–2060.78
Stage III a, b, d7.92
1.98–17.80
a, b, d241.20
26.00–554.70
a, b, d650.55
48.70–1810.60
a, b, d766.20
10.10–2742.00
Stage IV a, b, d12.27
2.00–27.40
a, b, d252.60
28.00–642.00
a, b372.95
37.80–1944.20
a, b, d541.13
14.30–8602.30
Total group a, b5.60
1.98–27.40
a, b170.79
4.60–839.00
a, b207.09
34.50–1944.20
a, b139.70
9.80–8602.30
Control groups Median Range Benign ovarian tumor total group 3.18
1.33–24.25
107.00
6.71–309.06
57.70
34.90–202.90
c22.90
5.80–748.00
Healthy subjects 3.25
1.75–8.42
128.88
23.38–266.09
54.00
15.00–408.89
12.70
1.49–36.60
  1. aStatistically significant when comparing EOC patients with healthy subjects
  2. bStatistically significant when comparing EOC patients with benign ovarian tumor total group
  3. cStatistically significant when comparing patients with benign ovarian tumor and healthy subjects
  4. dStatistically significant when comparing EOC patients in stage III or IV with stage I or II